This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RTTR vs. KALV, TRVI, KROS, PHAR, CAPR, SBTX, ORGO, CRMD, SVRA, and UPBShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include KalVista Pharmaceuticals (KALV), Trevi Therapeutics (TRVI), Keros Therapeutics (KROS), Pharming Group (PHAR), Capricor Therapeutics (CAPR), Silverback Therapeutics (SBTX), Organogenesis (ORGO), CorMedix (CRMD), Savara (SVRA), and Upstream Bio (UPB). These companies are all part of the "medical" sector. Ritter Pharmaceuticals vs. KalVista Pharmaceuticals Trevi Therapeutics Keros Therapeutics Pharming Group Capricor Therapeutics Silverback Therapeutics Organogenesis CorMedix Savara Upstream Bio Ritter Pharmaceuticals (NASDAQ:RTTR) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership. Does the media prefer RTTR or KALV? In the previous week, KalVista Pharmaceuticals had 5 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 5 mentions for KalVista Pharmaceuticals and 0 mentions for Ritter Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 1.39 beat Ritter Pharmaceuticals' score of 0.00 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Ritter Pharmaceuticals Neutral KalVista Pharmaceuticals Positive Does the MarketBeat Community favor RTTR or KALV? KalVista Pharmaceuticals received 47 more outperform votes than Ritter Pharmaceuticals when rated by MarketBeat users. Likewise, 75.05% of users gave KalVista Pharmaceuticals an outperform vote while only 70.23% of users gave Ritter Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRitter PharmaceuticalsOutperform Votes30270.23% Underperform Votes12829.77% KalVista PharmaceuticalsOutperform Votes34975.05% Underperform Votes11624.95% Which has more volatility & risk, RTTR or KALV? Ritter Pharmaceuticals has a beta of -0.43, meaning that its stock price is 143% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Which has better valuation & earnings, RTTR or KALV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRitter PharmaceuticalsN/AN/A-$10.13MN/AN/AKalVista PharmaceuticalsN/AN/A-$126.64M-$3.72-3.49 Do analysts recommend RTTR or KALV? KalVista Pharmaceuticals has a consensus price target of $24.83, suggesting a potential upside of 91.17%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Ritter Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ritter Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is RTTR or KALV more profitable? Ritter Pharmaceuticals' return on equity of 0.00% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ritter PharmaceuticalsN/A N/A -162.05% KalVista Pharmaceuticals N/A -103.92%-88.06% Do institutionals and insiders believe in RTTR or KALV? 0.8% of Ritter Pharmaceuticals shares are held by institutional investors. 15.4% of Ritter Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryKalVista Pharmaceuticals beats Ritter Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.97M$6.68B$5.44B$7.80BDividend YieldN/A3.20%5.44%4.30%P/E Ratio-5.697.1422.1418.39Price / SalesN/A238.89389.70101.30Price / CashN/A65.6738.2034.62Price / Book36.396.266.664.18Net Income-$10.13M$142.48M$3.21B$247.71M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$3.64-5.5%N/A+1,146.4%$167.97MN/A-5.697Gap DownKALVKalVista Pharmaceuticals4.3479 of 5 stars$12.01+0.1%$24.83+106.8%+24.4%$597.09MN/A-3.30100Positive NewsTRVITrevi Therapeutics3.3548 of 5 stars$6.02-0.8%$17.56+191.7%+139.6%$582.03MN/A-13.6820Positive NewsKROSKeros Therapeutics3.0524 of 5 stars$14.30+1.6%$40.33+182.1%-74.4%$580.04M$3.55M-2.74100Positive NewsPHARPharming Group2.6993 of 5 stars$8.15+0.7%$30.00+268.1%-13.2%$554.45M$297.20M-31.35280News CoveragePositive NewsGap UpCAPRCapricor Therapeutics1.7139 of 5 stars$11.92+6.0%$34.50+189.4%+163.5%$544.47M$22.27M-11.25N/ASBTXSilverback TherapeuticsN/A$14.88flatN/A+74.1%$536.54MN/A-6.1583High Trading VolumeORGOOrganogenesis3.2907 of 5 stars$4.21-0.2%$5.50+30.6%+52.0%$533.95M$482.04M-70.17950Positive NewsCRMDCorMedix2.6233 of 5 stars$8.14+6.1%$14.50+78.1%+71.7%$530.58M$43.47M-10.0530SVRASavara2.3205 of 5 stars$3.05+1.3%$8.83+189.6%-22.9%$526.53MN/A-7.09N/APositive NewsUPBUpstream BioN/A$9.71+10.6%$56.50+481.9%N/A$520.85M$2.37M0.0038 Related Companies and Tools Related Companies KalVista Pharmaceuticals Competitors Trevi Therapeutics Competitors Keros Therapeutics Competitors Pharming Group Competitors Capricor Therapeutics Competitors Silverback Therapeutics Competitors Organogenesis Competitors CorMedix Competitors Savara Competitors Upstream Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTTR) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RTTR Stock Free RTTR Stock Alerts